Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel

Authors:

Abstract
Approximately 2% of people worldwide have psoriasis, with as many as 1 million people with psoriasis in Canada alone. 1 , 2 The severity of psoriasis ranges from mild to severe. It can lead to substantial morbidity and psychological stress and have a profound negative impact on patient quality of life. 3 , 4 Although available therapies reduce therapies reduce the extent and severity of the disease and improve quality of life, 3 reports have indicated a patient preference for more aggressive therapy and a dissatisfaction with the effectiveness of current treatment options. 5

This publication has 68 references indexed in Scilit: